
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KG006
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Celltrion
Deal Size : $744.0 million
Deal Type : Licensing Agreement
Kaigene Signs Exclusive Deal with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
Details : Through the licensing deal for KG006, an unconjugated antibody targeting FcRn, the focus is on advancing treatment for autoimmune disorders.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $8.0 million
November 04, 2025
Lead Product(s) : KG006
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Celltrion
Deal Size : $744.0 million
Deal Type : Licensing Agreement

Contact Us!